白细胞介素-23 p19与白细胞介素-12 p40治疗肠道炎症的直接对比研究 - Suppr

Suppr

超能文献

Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation.

作者信息

Abraham Clara

机构信息

From Yale University, New Haven, CT.

出版信息

N Engl J Med. 2024 Jul 18;391(3):275-277. doi: 10.1056/NEJMe2405452.

DOI:10.1056/NEJMe2405452

PMID:39018537

Abstract

摘要

相似文献

Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation.

N Engl J Med. 2024 Jul 18;391(3):275-277. doi: 10.1056/NEJMe2405452.

Anti-IL-12/23 in Crohn's disease: bench and bedside.

Curr Drug Targets. 2013 Nov;14(12):1379-84. doi: 10.2174/13894501113146660229.

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22.

IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans.

J Allergy Clin Immunol. 2019 Dec;144(6):1731-1734.e1. doi: 10.1016/j.jaci.2019.08.014. Epub 2019 Aug 27.

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.

Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013.

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.

Ann N Y Acad Sci. 2009 Dec;1182:97-110. doi: 10.1111/j.1749-6632.2009.05070.x.

[Use of ustekinumab in inflammatory bowel disease: apropos of three cases].

Gastroenterol Hepatol. 2012 Jun-Jul;35(6):451-2. doi: 10.1016/j.gastrohep.2011.12.001. Epub 2012 Feb 7.

Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.

J Gastroenterol Hepatol. 2021 Jul;36(7):1744-1753. doi: 10.1111/jgh.15401. Epub 2021 Feb 3.

[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].

Gastroenterol Hepatol. 2011 Oct;34(8):546-50. doi: 10.1016/j.gastrohep.2011.04.003. Epub 2011 Jun 12.

Update on ustekinumab for the treatment of Crohn's disease.

Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation.

N Engl J Med. 2024 Jul 18;391(3):275-277. doi: 10.1056/NEJMe2405452.

Anti-IL-12/23 in Crohn's disease: bench and bedside.

Curr Drug Targets. 2013 Nov;14(12):1379-84. doi: 10.2174/13894501113146660229.

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22.

IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans.

J Allergy Clin Immunol. 2019 Dec;144(6):1731-1734.e1. doi: 10.1016/j.jaci.2019.08.014. Epub 2019 Aug 27.

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.

Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013.

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.

Ann N Y Acad Sci. 2009 Dec;1182:97-110. doi: 10.1111/j.1749-6632.2009.05070.x.

[Use of ustekinumab in inflammatory bowel disease: apropos of three cases].

Gastroenterol Hepatol. 2012 Jun-Jul;35(6):451-2. doi: 10.1016/j.gastrohep.2011.12.001. Epub 2012 Feb 7.

Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.

J Gastroenterol Hepatol. 2021 Jul;36(7):1744-1753. doi: 10.1111/jgh.15401. Epub 2021 Feb 3.

[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].

Gastroenterol Hepatol. 2011 Oct;34(8):546-50. doi: 10.1016/j.gastrohep.2011.04.003. Epub 2011 Jun 12.

Update on ustekinumab for the treatment of Crohn's disease.

Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013.